Compare AVLN & ASTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | ASTE |
|---|---|---|
| Founded | N/A | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2026 | 2003 |
| Metric | AVLN | ASTE |
|---|---|---|
| Price | $38.37 | $43.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $66.00 |
| AVG Volume (30 Days) | 163.8K | ★ 258.3K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.85% |
| EPS Growth | N/A | ★ 784.21 |
| EPS | N/A | ★ 0.51 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.72 |
| Revenue Next Year | N/A | $5.44 |
| P/E Ratio | ★ N/A | $82.10 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.90 | $40.47 |
| 52 Week High | $40.17 | $65.69 |
| Indicator | AVLN | ASTE |
|---|---|---|
| Relative Strength Index (RSI) | 67.65 | 36.48 |
| Support Level | $26.38 | $43.49 |
| Resistance Level | $40.08 | $47.56 |
| Average True Range (ATR) | 2.60 | 2.06 |
| MACD | 0.54 | -0.07 |
| Stochastic Oscillator | 94.55 | 19.91 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. The company has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.